Page last updated: 2024-10-21

4-aminopyridine and Granulocytic Leukemia, Chronic

4-aminopyridine has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research Excerpts

ExcerptRelevanceReference
" Second, we tested the therapeutic effect of VP16 combined with CCT245737, an orally bioavailable CHK1 inhibitor, and observed strong synergistic anticancer effects in K562 cells."1.56Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair. ( Fan, Z; Lai, Q; Li, S; Liang, A; Luo, H; Wang, F; Wang, G; Wang, J; Xu, J; Xu, Y; Zhang, W; Zhou, J, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Fan, Z1
Luo, H1
Zhou, J1
Wang, F1
Zhang, W1
Wang, J1
Li, S1
Lai, Q1
Xu, Y1
Wang, G1
Liang, A1
Xu, J1

Other Studies

1 other study available for 4-aminopyridine and Granulocytic Leukemia, Chronic

ArticleYear
Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
    Oncology reports, 2020, Volume: 44, Issue:5

    Topics: 4-Aminopyridine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Chec

2020
chemdatabank.com